|
Table 1: Characteristics according to the diagnosis of pulmonary hypertension. |
||||
|
Without PH N = 943, n (%) |
With PH N = 890, n (%) |
Total N = 1,833, n (%) |
p |
|
|
Male |
549 (58.2) |
507 (57.0) |
1,056 (57.6) |
0.588 |
|
Age [years] |
69 (59.8) |
71 (60.8) |
70 (59.8) |
0.002 |
|
Arterial hypertension |
695 (73.7) |
635 (71.3) |
1,330 (72.6) |
0.259 |
|
Alcoholism |
33 (3.5) |
28 (3.1) |
61 (3.3) |
0.673 |
|
Type 2 diabetes |
231 (24.5) |
212 (23.8) |
443 (24.2) |
0.735 |
|
Liver disease |
1 (0.1) |
5 (0.6) |
6 (0.3) |
0.088 |
|
Coronary heart disease |
252 (26.7) |
258 (29.0) |
510 (27.8) |
0.279 |
|
COPD |
110 (11.7) |
203 (22.8) |
313 (17.1) |
< 0.001 |
|
Atrial fibrillation |
164 (17.4) |
241 (27.1) |
405 (22.1) |
< 0.001 |
|
Thyroid disease |
130 (13.8) |
168 (18.9) |
298 (16.3) |
0.003 |
|
Chronic kidney disease |
142 (15.1) |
181 (20.3) |
323 (17.6) |
0.003 |
|
Valvulopathy |
825 (87.5) |
698 (78.4) |
1,523 (83.1) |
< 0.001 |
|
Coronary revascularization |
77 (8.2) |
55 (6.2) |
132 (7.2) |
0.100 |
|
Dyslipidemia |
240 (25.5) |
258 (29.0) |
498 (27.2) |
0.089 |
|
Smoking |
150 (15.9) |
175 (19.7) |
325 (17.7) |
0.035 |
|
Anemia |
262 (29.0) |
282 (33.4) |
544 (31.1) |
0.049 |
|
Chagas disease |
29 (3.1) |
30 (3.4) |
59 (3.2) |
0.720 |
|
NYHA functional class I II III IV |
140 (14.8) 521 (55.2) 253 (26.8) 29 (3.1) |
87 (9.8) 462 (51.9) 284 (31.9) 57 (6.4) |
227 (12.4) 983 (53.6) 537 (29.3) 86 (4.7) |
< 0.001 – – – – |
|
Use of medications ACEIs/ARBs-II Beta-blockers ARNI MRA Ivabradine Diuretics Nitrates Anti-aggregants Statins Anticoagulants |
699 (74.1) 810 (85.9) 91 (9.7) 534 (56.6) 68 (7.2) 590 (62.6) 41 (4.3) 463 (49.1) 531 (56.3) 199 (21.1) |
660 (74.2) 775 (87.1) 88 (9.9) 513 (57.6) 54 (6.1) 659 (74.0) 33 (3.7) 394 (44.3) 504 (56.6) 268 (30.1) |
1,359 (74.1) 1,585 (86.5) 179 (9.8) 1,047 (57.1) 122 (6.7) 1,249 (68.1) 74 (4.0) 857 (46.8) 1,035 (56.5) 467 (25.5) |
0.987 0.459 0.864 0.662 0.326 < 0.001 0.487 0.038 0.890 < 0.001 |
|
PASP (mmHg)* |
120 [110-135] |
119 [104-131] |
120 [107-134] |
0.011 |
|
Heart rate (bpm)* |
72 [65-80] |
72 [65-84] |
72 [65-81] |
0.117 |
|
LVDD (mm)* |
56 [48-65] |
57 [48-65] |
57 [48-65] |
0.257 |
|
LVEF* |
35 [25-42] |
30 [24-42] |
33 [25-42] |
0.002 |
|
Hemoglobin (mg dL)* |
13 [11.7-14.4] |
13 [11.6-14.3] |
13 [11.6-14.4] |
0.549 |
|
NT-proBNP* |
1,723.500 [571.3-4,911.5] |
3,581 [1,428.3-8,692.3] |
2,407.500 [954-6,043.3] |
< 0.001 |
|
Prolonged QRS |
171 (30.2) |
218 (42.4) |
389 (36.0) |
< 0.001 |
|
ACEIs = Angiotensin-converting enzyme inhibitors ARBs = angiotensin receptor antagonists. ARNI = angiotensin receptor neprilysin inhibitor bpm = beats per minute. COPD = chronic obstructive pulmonary disease. LVDD = left ventricular diastolic diameter. LVEF= left ventricular ejection fraction. MRA = aldosterone receptor antagonists. NT-proBNP = N-terminal pro B-type natriuretic peptide NYHA = New York Heart Association. PH = pulmonary hypertension. SBP = systolic blood pressure. *Median and [interquartile range]. |
||||